Company Overview of Yeda Research and Development Company Ltd.
Yeda Research and Development Company Ltd., a technology transfer company, markets and commercializes intellectual properties that are created in the laboratories of Weizmann Institute of Science. The company identifies and assesses research projects with commercial potential, protects the intellectual property of the institute and its scientists, licenses the institute’s inventions and technologies to industry, and channels funding from industry to research projects. It markets and commercializes intellectual properties that cover a range of natural sciences, including biotechnology, pharmaceuticals, and diagnostics; bioinformatics, proteomics, biomatics, and system biology; medical devices...
Weizman Institue of Science
de Botton Building (Building No. 5)
P.O. Box 95
Founded in 1959
Key Executives for Yeda Research and Development Company Ltd.
Chief Intellectual Property Officer
Compensation as of Fiscal Year 2015.
Yeda Research and Development Company Ltd. Key Developments
Sun Pharma Announces Research Collaboration with Yeda Research and Development Company Ltd. and Fundacion Ramón Domínguez
Dec 10 15
Sun Pharmaceutical Industries Ltd. entered into a tripartite research and option agreement with Weizmann Institute of Science and Spain's Health Research Institute of Santiago de Compostela (IDIS) to develop breakthrough products for the treatment of neurological diseases like brain stroke; as well as glioblastoma. Scientists at Weizmann Institute have developed a recombinant enzyme currently undergoing animal studies for indications of brain stroke and glioblastoma. Further studies of this enzyme will be conducted at the Health Research Institute of Santiago de Compostela in Spain. Moreover, this enzyme may potentially be indicated for uses beyond these two brain diseases. As per the signed triparty agreement, Sun Pharma will have the first right to develop these additional indications. Sun Pharma will have the exclusive option to conduct further development of the enzyme after completion of the preclinical studies. The company will have commercial rights to this product globally. It will also fund all future studies to be conducted on the enzyme. The tripartite research collaboration agreement has been signed between Sun Pharma, Yeda Research & Development Company Ltd. and Fundacion Ramón Domínguez. Based on outcome of animal studies, Sun Pharma will have an option to exercise rights for further development and commercialization of the enzyme.
TxCell SA Enters into Exclusive Option Agreement with Yeda Research and Development
Nov 2 15
TxCell SA announced that it has entered into an exclusive option agreement with Yeda Research and Development Co. Ltd. Resulting from the exclusive option agreement, TxCell will gain exclusive access to a CAR-Treg patent for suppression of autoimmune and inflammatory diseases originated in the Weizmann Institute of Science laboratory of Professor Zelig Eshhar. The patent application under the option that TxCell has obtained covers redirected, genetically engineered T regulatory cells (CAR-Treg) and their use in suppression of autoimmune and inflammatory diseases. The option agreement grants TxCell until June 30, 2016 to opt-in at predefined terms.
Yeda Presents at BIO-Europe 2015, Nov-03-2015 02:50 PM
Oct 21 15
Yeda Presents at BIO-Europe 2015, Nov-03-2015 02:50 PM. Venue: Munich, Germany.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
Most Searched Private Companies
Sponsored Financial Commentaries